BioSpace News Archive

Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple disciplines and functions, has been appointed Chief Sustainability Officer effective immediately.

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced the publication of data in the journal Gene Therapy showing that EBT-001 – a simian-specific analogue of EBT-101 – safely removes the simian form of HIV from the genomes of non-human primates.

Processa Pharmaceuticals, Inc. provides an interim analysis from its ongoing Phase 1B trial of Next Generation Capecitabine (NGC-Cap) in patients with gastrointestinal cancer, which identifies a personalized treatment approach that may yield improved safety and treatment efficacy.

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the interim report for the six months ended June 30, 2023 and provided a corporate update.

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant entitled “Quantification of Cys106 of DJ-1 in Distinct Redox States in Parkinson’s Patients’ iPSC-derived Dopaminergic Neurons, Postmortem Brain Tissue and Plasma as a Potential Biomarker of Parkinson’s Disease”.

Nephron Pharmaceuticals Corporation today announced Julie Rameas as Chief Procurement Officer.

Bloom Science, Inc. today announced positive results from its Phase 1 clinical study in healthy volunteers that demonstrate a favorable safety, tolerability and strain kinetics profile of BL-001, an orally-delivered Live Biotherapeutic Product (LBP).

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302.

Visiox Pharmaceuticals, Inc. is pleased to announce that Richard J. Rubino has been appointed to serve on the Company’s Board of Directors as the Chairman of the Audit Committee.